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Abstract
Aims Sirtuin-1 (SIRT-1) down-regulation in type 2 diabetes mellitus (T2DM) has been associated with epigenetic markers 
of oxidative stress. We herein aim to evaluate whether an increase in SIRT-1 expression affects histone 3 acetylation at the 56 
lysine residue (H3K56ac) in T2DM patients randomly selected to receive either resveratrol (40 mg or 500 mg) or a placebo 
for 6 months. The primary outcome is changes in the H3K56ac level by variation in SIRT-1 expression and the secondary 
outcome is the evidence of association between SIRT-1 level, antioxidant markers (TAS), and metabolic variables.
Methods and results At baseline, peripheral blood mononuclear cell H3K56ac values among the SIRT-1 tertiles did not 
differ. At trial end, SIRT-1 levels were significantly higher in patients receiving 500 mg resveratrol. At follow-up, patients 
were divided into tertiles of delta (trial end minus baseline) SIRT-1 value. Significant reductions in H3K56ac and body fat 
percentage were found in the highest tertile as were increased TAS levels. A multiple logistic regression model showed that 
the highest delta SIRT-1 tertile was inversely associated with variations in H3K56ac (OR = 0.66; 95% CI 0.44–0.99), TAS 
(OR = 1.01; 95% CI 1.00–1.02), and body fat percentage (OR = 0.75; 95% CI 0.58–0.96).
Conclusions We provide new knowledge on H3K56ac and SIRT-1 association in T2DM. These data suggest that boosting 
SIRT-1 expression/activation may impact redox homeostasis in these patients.
ClinicalTrials.gov Identifier NCT02244879.
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Introduction
Chronic diseases, including obesity and diabetes mellitus 
(T2DM), correlate with redox homeostasis imbalance. 
Mitochondrial reactive oxygen species (ROS) generation 
is considered the major regulator of hyperglycemia-medi-
ated epigenetic changes, including histone (H) posttrans-
lational modifications [1, 2]. In particular, H3K terminal 
tail acetylation largely results in gene transcription after 
genotoxic damage [3, 4]. Lo et al. [5] have recently shown 
that the highest H3 acetylation level at the 56 lysine residue 
(H3K56ac) is associated with proteins and transcription fac-
tors involved in T2DM signaling pathways in half of the 
mature adipocyte genome. H3K56 is deacetylated by the 
class III histone deacetylase (HDAC) sirtuins [3, 4]. One sir-
tuin family member, SIRT-1, was found persistently down-
regulated in T2DM patients [6] and has been associated with 
mitochondrial ROS accumulation and increased p53 acety-
lation (p53ac) levels [7, 8]. Little data on the association 
between SIRT-1 and H3K56ac have been provided [3, 4, 9].
Resveratrol, 3,5,4′-trihydroxy-trans-stilbene, activates 
SIRT-1 and is a ROS scavenger [10]. Its benefits in human 
disease are highly controversial since not all the beneficial 
properties described in preclinical studies have been con-
firmed by clinical trials [11, 12], and concerns about its 
favorable effects were recently raised by systematic reviews 
and position statements [13–15]. We recently failed to detect 
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any metabolic benefits of resveratrol in T2DM patients with-
out vascular complications [16].
We therefore aimed to evaluate whether variations 
of SIRT-1 expression were associated with changes in 
H3K56ac and p53ac levels, and/or with modifications of 
oxidative stress markers, inflammatory or metabolic vari-
ables in T2DM patients. Peripheral blood mononuclear 
cells (PBMCs) were used as surrogates to evaluate SIRT-1, 
H3K56ac, and p53ac content. Unexpectedly, not all patients 
receiving resveratrol showed increased SIRT-1 expression/
activation. Data were therefore analyzed by dividing par-
ticipants according to increased SIRT-1 value, regardless of 
resveratrol treatment.
Methods
Study design and intervention
This was an observational study nested on a randomized 
controlled trial, which has previously been described [16, 
17] and was registered at: www.clin ical tria ls (Identifier: 
NCT02244879). Briefly, 192 T2DM patients were recruited 
from the Diabetic Clinic of the University of Turin from 
October 2013 through February 2016.
The inclusion criteria were: T2DM, age ≥ 40 years, body 
mass index (BMI) < 35 kg/m2, patients on diet and/or hypo-
glycemic agents other than insulin. Exclusion criteria were: 
treatment with any antioxidant substance, treatment with 
insulin, anticoagulants, steroids, or anti-inflammatory drugs 
different from aspirin, alcohol or substance abuse, uncom-
pensated diabetes, liver or kidney diseases, presence of dia-
betes-related chronic complications, cardiovascular events 
or revascularization procedures in the previous 4-weeks, 
any severe chronic or life-threatening diseases, pregnancy, 
allergy to peanuts, grapes, wine, mulberries.
All patients recruited from March 2014 until February 
2016 (n = 128) were enrolled for this study. All procedures 
were in agreement with the principles of the Helsinki Dec-
laration; the study protocol was approved by the local eth-
ics committee. All participants provided written informed 
consent.
Patients were randomized to one capsule/day of resver-
atrol 500 mg/day (Resv500 arm), one capsule/day of res-
veratrol 40 mg/day (Resv40 arm), and one capsule/day of 
placebo (totally inert microcellulose) (Placebo arm), respec-
tively, for 6 months. Biotivia Bioceuticals (International SrL, 
Italy) prepared all the capsules, which were identical in size, 
shape, color, and taste. High-pressure liquid chromatography 
analyses revealed 99.7 and 97.9% trans-resveratrol purity in 
500 mg and 40 mg capsules, respectively, and no resveratrol 
content in placebo capsules.
Patients and researchers who dispensed the capsules, col-
lected data, and were involved in all measurements were 
blinded to the bottle content.
Participants were allocated as follows: 43, 43, and 42 in 
the Resv500, Resv40, and Placebo arms, respectively. All 
patients took medication in the morning and maintained 
their habitual lifestyle, the diet given by the Diabetic Clinic, 
their current hypoglycemic treatment and were instructed 
to abstain from nutritional supplements and significant 
amounts of resveratrol-rich foods and beverages [12, 16]. 
Compliance with the study protocol was monitored with 
monthly phone calls and pill counting.
Patients were stratified by acetylsalicylic acid use and gly-
cated hemoglobin (HbA1c) levels (cut-point 7%), according 
to a computer-generated randomization sequence [16, 17].
Outcomes
Primary outcome Association between changes in SIRT-1 
level and variation in H3K56ac value.
Secondary outcomes Association between changes in 
SIRT-1 level and variation in p53ac, oxidative stress markers 
(total antioxidant status: TAS), anthropometric, metabolic, 
and inflammatory variables.
Measurements
Body weight and height were measured with light clothes 
and no shoes. Waist circumference was measured at the nar-
rowest level by a plastic tape meter. Body composition was 
determined by dual X-ray densitometry (QDR-4500 Hologic 
Inc., Bedford, MA, USA), using whole-body absorptiom-
etry software. Arterial blood pressure values were measured 
twice from the left arm, in a sitting position, after at least 
10-min rest, with a mercury sphygmomanometer with appro-
priate cuff sizes (ERKA Perfect-Aneroid, Germany). The 
homeostasis model assessment-insulin resistance (HOMA-
IR) was calculated according to the published algorithm.
Blood sample analysis
Blood samples were freshly collected from each participant 
at baseline and at trial end. The laboratory measurements 
were blindly performed at the Laboratories of the Depart-
ment of Medical Sciences, University of Turin.
The human PTX3 was measured by a ready-to-use 
solid-phase enzyme-linked immunosorbent assay based 
on the sandwich principle (Hycult biotech, Uden, The 
Netherlands). The intra-assay and inter-assay CVs were 
3.6–3.8 and 4.1–4.9%, respectively. TAS measurement was 
performed with a colorimetric assay (ImAnOx TAS Kit, 
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Immundiagnostik AG Bensheim, Germany), with intra-assay 
and inter-assay CVs of 2.0–4.0 and 2.6–3.9%, respectively.
Serum C-reactive protein (CRP) values were deter-
mined using a high-sensitivity latex agglutination assay 
on HITACHI 911 Analyzer (Sentinel Ch., Milan, Italy). 
The intra-assay and inter-assay CVs were 0.8–1.3 and 
1.0–1.5%, respectively. Interleukin-6 (IL-6) circulating 
concentrations were measured by a quantitative sandwich 
enzyme immunoassay technique (R&D System, Minne-
apolis, MN, USA) with an intra-assay CV of 6.9% and an 
inter-assay CV of 7.2%.
Serum glucose was measured by the glucose oxidase 
method (Sentinel Ch., Milan) with an intra-assay CV of 
1.1% and an inter-assay CV of 2.3%. Triglycerides and 
cholesterol were assayed by enzymatic colorimetric assays 
(Sentinel Ch., Milan) with an intra-assay CV of 3.0% and 
an inter-assay CV of 3.5% for triglycerides and with an 
intra-assay CV of 2.2% and an inter-assay CV of 3.4% 
for cholesterol. HDL-cholesterol was determined by enzy-
matic colorimetric assay after precipitation of LDL and 
VLDL fractions using heparin–MnCl2 solution and cen-
trifugation at 4 °C, and it had an intra-assay CV of 2.5% 
and an inter-assay CV of 4.1%. Free fatty acid (FFA) val-
ues were assayed by an enzymatic colorimetric method 
(RANDOX, UK).
Alanine aminotransferase (ALT) and ɣ-glutamyl-
transferase (GGT) were measured by a kinetic determi-
nation (Sentinel Ch., Milan) according to the IFCC rec-
ommendations. Insulin was measured by a biotin labeled 
antibody based sandwich enzyme immunoassay (LDN, 
Germany). The kit had a sensitivity of less than 1.8 μU/
ml and a range of 0–100 μU/ml. The intra-assay and inter-
assay CVs were 1.8–2.6 and 2.9–6.0%, respectively. Gly-
cated hemoglobin (Hba1c) was determined with a latex-
based method (Sentinel Ch., Milan). The intra-assay and 
inter-assay CVs were 1.1–1.5 and 1.1–1.6%, respectively. 
Adiponectin was measured by sandwich enzyme-linked 
immunosorbent assays (BioVendor, Brno, Czech Repub-
lic). The kit has a sensitivity of 470 ng/ml and a range of 
5000 to 150,000 ng/ml. The intra- and inter-assay CVs 
were 4.1 and 6.9%, respectively. Uric acid was assayed by 
uricase-based enzymatic colorimetric assays (Sentinel Ch., 
Milan) with an intra-assay CV of 2.1% and an inter-assay 
CV of 1.7%.
Peripheral blood mononuclear cell (PBMC) preparation
Blood sample (14 mL) was freshly collected from each 
patient participating in the randomized controlled trial 
(RCT) at baseline and at the end of treatment. PBMCs 
were isolated by Ficoll-Paque (Histopaque 1077; Sigma-
Aldrich) density gradient centrifugation (400 g for 30 min 
at RT), washed twice with saline phosphate buffer (PBS) 
(300 g for 10 min at 4 °C), and lysed using a lysis buffer 
for nuclear protein extraction.
Western blot analysis
PBMCs were lysed as previously described [18]. Proteins 
(50 µg) were subjected to SDS-PAGE, transferred into nitro-
cellulose membrane, blotted with the indicated antibodies, 
and processed. Densitometric analysis was used to calculate 
the differences in the fold induction of protein levels nor-
malized to β-actin, H3, and p53 content. Twenty samples, 
randomly selected, were double analyzed, and similar results 
were obtained. Values are reported as relative amounts (ra). 
All experiments were blindly performed.
Statistics
Within-group differences among the three arms were evalu-
ated using the Wilcoxon matched-pairs test, while between-
group differences were computed using the Kruskal–Wallis 
test.
Participants were divided according to tertiles of the 
baseline SIRT-1 values; the highest tertile (SIRT-1 ≥ 1.16ra) 
was compared with the other two. The differences between 
end-of-the-trial values and each variable’s baseline value 
(delta) were calculated. Delta SIRT-1 tertiles were then 
computed; analyzed variable delta values were compared 
with the highest tertile of delta SIRT-1 (≥ 0.66ra) and the 
other two.
Either the Student’s t test or the Mann–Whitney U test 
(non-normally distributed variables) was used to investigate 
differences in the variables between SIRT-1 value tertiles.
Associations between the highest tertile of delta SIRT-1 
values and the median values of delta H3K56ac, delta TAS, 
and delta percent body fat were evaluated using a multiple 
logistic regression model, after adjustments for age, gender, 
and resveratrol treatment.
The power of the study, calculated by using the Wil-
coxon test for delta H3K56ac mean values, was 0.82 with 
α-value = 0.05.
Results
Baseline expression of SIRT‑1 and its targets, 
H3K56ac and p53ac
Mean ± SD and median (interquartile range) baseline val-
ues of SIRT-1 in T2DM patients were 1.04 ± 0.71 and 0.86 
(0.93) ra. Table 1 shows patient characteristics, by SIRT-1 
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tertiles at baseline (the highest tertile was compared to the 
lowest two tertiles). We found that patients in the high-
est tertile showed higher HbA1c values. No differences in 
H3K56ac and p53ac values were detected in the two groups.
Increased SIRT‑1 expression correlates 
with a reduction in H3K56ac, but not p53ac
The following dropouts occurred at follow-up: two (Placebo 
arm), two (Resv40 arm), one (Resv500 arm). At trial end, 
the mean ± SD and median (interquartile range) values of 
SIRT-1 were 1.37 ± 1.65 and 0.97 (1.23) ra. The mean delta 
SIRT-1 value was 0.36ra. The values of SIRT-1, by trial arm, 
are reported in Table 2. Within-group SIRT-1 values signifi-
cantly increased at trial end in the Resv500 group (p < 0.001 
by Wilcoxon test), and the delta values differed among the 
groups. Median H3K56ac and p53ac values did not dif-
fer among arms of treatment. The median delta values for 
each analyzed variable, by delta SIRT-1 tertiles, are shown 
in Table 3 (left side). A significantly higher proportion of 
Resv500 arm patients showed higher increases in SIRT-1 
value. Patients in the highest delta SIRT-1 tertile displayed 
a significant decrease in H3K56ac. No significant differences 
in p53ac expression levels were detected. SIRT-1, H3K56ac, 
and p53ac expression levels for six patients in each arm are 
reported in Figs. 1 and 2.
The deltas of the different variables, by SIRT-1 varia-
tion, were calculated after excluding patients from the 
Placebo arm (Table 2, right side). Patients in the highest 
SIRT-1 value tertile still displayed a significant reduction 
in H3K56ac levels.
Table 1  Baseline characteristics 
of T2DM patients by SIRT-1 
tertiles
BMI body mass index, HOMA-IR homeostasis model assessment-insulin resistance, ra relative amount
*P obtained by Student’s t test or Chi-square, as appropriate
**Median (interquartile range); P obtained by Mann–Whitney U test
Baseline variables Lower tertiles (< 1.16 ra) Highest tertile (≥ 1.16 ra) P*
Number 86 42
Males (%) 67.4 54.8 0.16
Age (years) 65.6 ± 7.3 64.0 ± 9.4 0.31
Weight (kg) 80.3 ± 12.5 83.8 ± 15.8 0.18
BMI (kg/m2) 29.1 ± 3.7 30.2 ± 3.6 0.13
Waist circumference (cm) 102.7 ± 9.7 105.5 ± 11.3 0.15
Percent body fat 33.5 ± 6.7 35.6 ± 7.3 0.10
Systolic blood pressure (mmHg) 132.1 ± 10.1 132.1 ± 8.4 0.98
Diastolic blood pressure (mmHg) 80.7 ± 8.2 80.4 ± 7.6 0.87
Fasting glucose (mg/dl) 138.8 ± 33.3 145.0 ± 43.5 0.37
Glycated hemoglobin (%) (mmol/mol) 6.75 ± 0.86 7.16 ± 1.34 0.038
50.3 ± 9.4 54.7 ± 14.6
Fasting C-peptide (nmol/l) 0.95 ± 0.44 1.05 ± 0.48 0.21
Fasting insulin (µU/ml)** 16.2 (11.0) 18.2 (10.6) 0.34
HOMA-IR (mmol/L × µU/ml)** 5.29 (4.03) 5.41 (4.02) 0.26
Total cholesterol (mg/dl) 176.6 ± 37.9 184.6 ± 40.9 0.28
Triglycerides (mg/dl)** 106.5 (86.0) 111.0 (77.0) 0.52
HDL-cholesterol (mg/dl) 46.7 ± 12.9 44.6 ± 10.2 0.38
LDL-cholesterol (mg/dl) 103.1 ± 34.3 112.9 ± 34.0 0.13
Free fatty acids (mmol/l) 0.66 ± 0.19 0.69 ± 0.19 0.40
Pentraxin-3 (ng/ml)** 0.81 ± 0.58 0.70 ± 0.39 0.29
Interleukin-6 (pg/ml)** 2.83 (2.38) 2.41 (1.43) 0.13
C-reactive protein (mg/dl)** 1.52 (2.47) 1.56 (3.67) 0.66
Adiponectin (ng/ml)** 7545.1 (4746.5) 7188.9 (5974.1) 0.72
Total antioxidant status (µmol/L) 294.2 ± 41.0 291.3 ± 41.4 0.71
Uric acid (mg/dl) 5.7 ± 1.4 5.4 ± 1.2 0.23
Alanine aminotransferase (U/l) 19.5 ± 9.6 18.7 ± 8.9 0.65
ɣ-glutamyl-transferase (U/l)** 23.0 (19.0) 25.0 (18.0) 0.83
H3K56ac (ra)** 0.88 (0.85) 0.96 (1.12) 0.39
p53ac (ra) 0.78 ± 0.53 0.90 ± 0.64 0.27
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In a multiple logistic regression model, the highest delta 
SIRT-1 tertile was inversely associated with H3K56ac vari-
ation and directly related to resveratrol supplementation in 
all patients (Table 4). These associations were no longer 
statistically significant after excluding patients from the 
Placebo arm.
Increased SIRT‑1 expression was directly associated 
with total antioxidant status
Highest delta SIRT-1 tertile patients showed significant 
increments in TAS values (Table 3), and that were still evi-
dent after excluding Placebo arm individuals. The direct 
association between median delta SIRT-1 values and 
delta TAS was confirmed by multiple regression analyses 
(Table 4).
Comparison between SIRT‑1 expression 
and metabolic and inflammatory variables
Individuals in the highest SIRT-1 tertile showed a signifi-
cant percentage body fat decrease (Table 3). This significant 
inverse relationship was confirmed using a multiple regres-
sion model (Table 4), but not after excluding the Placebo 
group.
No other metabolic variable was associated with changes 
in SIRT-1 expression. Similarly, no association between 
SIRT-1 change and inflammatory variables was found.
Discussion
We herein report that, at 6-month follow-up, increased 
SIRT-1 expression was associated with significant H3K56ac 
content reduction and increased serum antioxidant activity 
in T2DM patients.
SIRT-1 is a nicotinamide adenine dinucleotide (NAD)-
dependent deacetylase, involved in the deacetylation of 
histones and nonhistone proteins, including transcription 
factors, proteins and enzymes implicated in cell differen-
tiation, cell survival, and metabolism [19, 20]. p53 was the 
first SIRT-1 target to be identified [21]. However, SIRT-1 
also deacetylates H3K56, a crucial regulator of chroma-
tin assembly/disassembly, which mainly marks transcrip-
tionally active genes after genotoxic cues [3, 4]. More 
recently, genome-wide analysis demonstrated that highest 
levels of H3K56 acetylation are associated with diabetes-
related genes [5]. Indeed, changes in histone acetylation 
have a central role in sustaining the long-lasting effects 
of hyperglycemia mechanistically defined as “metabolic 
memory” [22]. As a matter of fact, SIRT1 also controls 
mitochondrial function and biogenesis, and free radical 
formation, key cues associated with epigenome reprogram-
ming in diabetes [23]. Resveratrol is one of the most active 
polyphenols to stimulate SIRT-1 activity [24], which is 
known to be reduced in T2DM patients [6]. Therefore, 
we aimed to investigate whether rescue of SIRT-1 expres-
sion/activation could influence diabetes-related oxidative 
stress via H3K56 deacetylation. Unexpectedly, we found 
that not all T2DM patients receiving resveratrol displayed 
increased SIRT-1 expression/activation. Nevertheless, the 
increase in SIRT-1 expression was associated with changes 
in H3K56ac.
PBMCs were used as surrogates to evaluate SIRT-1 
expression, while p53 and H3K56 acetylation were used as 
markers of its activation. A significant and dose-dependent 
increase in SIRT-1 expression was found after resveratrol 
supplementation. However, not all resveratrol arm patients 
showed an increase in SIRT-1 value at trial end. Changes in 
lifestyle and/or dietary intake, such as resveratrol-rich foods 
and beverages during the trial, may have caused unpredict-
able environmental conditions which may have influenced 
SIRT-1 expression. Moreover, genetically determined vari-
ants of the individual response to resveratrol treatment may 
also be postulated. Finally, the possibility of SIRT-1 being 
a direct target of resveratrol has been questioned [25], while 
both SIRT-1-independent effects [26] and decreased SIRT-1 
levels [27] have been reported after resveratrol treatment.
Particular attention has recently been dedicated to the 
identification of oxidative stress-induced epigenetic T2DM 
markers [8]. Indeed, increased HDAC3 activity in PBMCs 
from T2DM patients has been directly correlated with 
Table 2  Median values of SIRT-1, H3K56ac, and P53ac, expressed 
as relative amounts, after treatment with resveratrol or placebo
Delta end of trial minus baseline value; median (interquartile range)
P values obtained by Kruskal–Wallis test
Placebo Resv40 Resv500 P
SIRT-1
Baseline 0.93 (1.00) 0.81 (1.01) 0.79 (0.79) 0.74
Trial end 0.79 (0.82) 0.90 (1.18) 1.16 (1.64) 0.14
Delta − 0.16 (1.33) 0.01 (1.36) 0.45 (1.21) 0.046
H3K56ac
Baseline 0.87 (1.06) 0.85 (1.02) 1.04 (0.96) 0.56
Trial end 1.09 (0.69) 1.16 (0.86) 1.27 (0.93) 0.90
Delta 0.34 (1.18) 0.12 (1.04) 0.03 (1.26) 0.70
P53ac
Baseline 0.89 (0.76) 0.79 (0.85) 0.51 (1.01) 0.06
Trial end 0.81 (0.69) 1.06 (0.99) 0.93 (0.78) 0.25
Delta 0.06 (0.60) 0.22 (0.92) 0.19 (0.88) 0.94
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inflammation and insulin resistance, and negatively with 
SIRT-1 level [28]. Accordingly, HDAC activity suppression 
in embryos subjected to hyperglycemia-induced oxidative 
stress resulted in increased H3K56ac level [29]. H3K56ac 
has been linked to the activation of genes related to the 
unbalance of redox signals [3, 5, 9]. The inverse relation-
ship between SIRT-1 level and H3K56ac is consistent with 
the original observation that antioxidant treatments reduced 
H3K56ac [3]. The significant correlation between increased 
serum antioxidant activity and SIRT-1/H3K56ac expression 
may be a proof of concept.
T2DM is characterized by low-grade chronic inflam-
mation, which has been linked to low sirtuin levels [30]. 
A close connection between SIRT-1 and p53ac has been 
reported, primarily in diabetes-associated vascular dys-
function/inflammation [8, 30]. Long-lasting diabetes 
(median value: 8-y) is a relevant feature in our patients. 
An impaired adaptive SIRT-1-mediated counter-acting 
response to environmental cues may therefore be a pos-
sible explanation for the failure to find correlation between 
SIRT-1, p53ac, and inflammatory parameters. Alterna-
tively, the low sample size may have masked small, but 
Table 3  Median value of deltas (end-of-trial value minus baseline value) for each of the analyzed variables by tertiles of delta SIRT-1 in all par-
ticipants (left side) and after excluding individuals from the Placebo arm (right side)
Median (interquartile range) *P obtained by Mann–Whitney U test or Chi-square, as appropriate
BMI body mass index, HOMA-IR homeostasis model assessment-insulin resistance, FFA free fatty acids, ALT alanine aminotransferase, GGT 
ɣ-glutamyl-transferase, ra relative amount
Lower tertiles (< 0.66 ra) Highest tertile (≥ 0.66 ra) P* Lower tertiles Highest tertile P*
Number 83 40 50 33
SIRT-1 (ra) − 0.23 (0.73) 1.29 (0.91) <0.001 − 0.14 (0.53) 1.28 (1.04) <0.001
Placebo arm (%) 39.8 17.5 – –
Resv40 arm (%) 33.7 32.5 56.0 39.4
Resv500 arm (%) 26.5 50.0 0.014 44.0 60.6 0.14
Males (%) 61.5 70.0 0.35 60.0 63.6 0.74
Weight (kg) − 0.50 (2.50) − 0.10 (3.75) 0.82 − 0.25 (3.00) − 0.20 (4.00) 0.77
BMI (kg/m2) 0.00 (0.90) − 0.057 (1.35) 0.82 0.00 (1.28) − 0.09 (1.39) 0.43
Waist circumference (cm) 1.75 (6.75) 0.00 (5.00) 0.55 0.00 (4.50) 1.50 (6.50) 0.52
Percent body fat 0.20 (1.80) − 0.60 (3.00) 0.018 0.00 (1.80) − 0.45 (3.00) 0.13
Systolic blood pressure (mmHg) 0.00 (12.0) 0.00 (12.5) 0.71 0.00 (10.0) 0.00 (10.0) 0.41
Diastolic blood pressure (mmHg) 0.00 (10.0) 0.00 (15.0) 0.60 0.00 (12.0) 0.00 (10.0) 0.17
Fasting glucose (mg/dl) 2.00 (27.0) − 2.00 (24.5) 0.32 2.00 (20.0) 1.00 (21.0) 0.28
Glycated hemoglobin (%) (mmol/
mol)
0.30 (1.40) 0.25 (1.15) 0.20 0.35 (1.30) 0.20 (1.10) 0.22
3.28 (15.3) 2.73 (12.6) 3.83 (14.2) 2.19 (12.0)
Fasting C-peptide (nmol/l) − 0.040 (0.43) − 0.06 (0.47) 0.45 − 0.02 (0.47) − 0.08 (0.47) 0.21
Fasting insulin (µU/ml) 2.89 (9.76) 0.32 (9.29) 0.26 2.89 (12.8) 1.81 (9.26) 0.28
HOMA-IR (mmol/L × µU/ml) 1.04 (3.75) 0.17 (3.39) 0.22 1.13 (5.03) 0.28 (2.94) 0.32
Total cholesterol (mg/dl) − 7.50 (43.0) − 1.00 (48.0) 0.31 − 4.00 (38.0) − 3.00 (50.0) 0.76
Triglycerides (mg/dl) 13.00 (55.0) 12.50 (45.5) 0.66 16.0 (71.0) 14.0 (46.0) 0.40
HDL-cholesterol (mg/dl) 2.00 (12.0) 2.50 (10.0) 0.37 2.00 (12.0) 3.00 (11.0) 0.16
LDL-cholesterol (mg/dl) − 6.50 (34.0) − 4.50 (41.5) 0.48 − 3.50 (32.0) − 3.00 (43.0) 0.95
FFA (mmol/l) 0.01 (0.04) 0.01 (0.04) 0.93 0.01 (0.06) 0.01 (0.04) 0.79
Pentraxin-3 (ng/ml) 0.04 (0.60) 0.08 (0.62) 0.82 0.13 (0.71) 0.00 (0.60) 0.36
Interleukin-6 (pg/ml) 0.19 (1.64) − 0.27 (1.60) 0.16 0.32 (1.84) − 0.23 (1.70) 0.33
C-reactive protein (mg/dl) − 0.02 (2.51) 0.00 (2.22) 0.38 0.00 (2.63) 0.01 (2.22) 0.54
Adiponectin (ng/ml) 137.4 (3583.8) 653.0 (3555.4) 0.71 − 449.6 (3763.8) 463.3 (3217.0) 0.43
Total antioxidant status (µmol/L) − 2.00 (62.0) 13.5 (72.0) 0.033 4.00 (70.0) 25.0 (66.0) 0.047
Uric acid (mg/dl) 0.00 (1.40) 0.30 (1.25) 0.32 0.05 (1.50) 0.30 (1.20) 0.44
ALT (U/l) 2.00 (11.0) − 1.00 (12.5) 0.12 1.00 (13.0) − 1.00 (14.0) 0.21
GGT (U/l) 1.00 (7.00) 0.00 (8.00) 0.68 2.00 (9.00) 0.00 (9.00) 0.29
H3K56ac (ra) 0.34 (0.95) − 0.20 (1.40) 0.025 0.25 (1.04) − 0.22 (1.37) 0.028
P53ac (ra) 0.10 (0.80) 0.32 (1.02) 0.24 0.18 (0.74) 0.40 (1.30) 0.50
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meaningful beneficial SIRT-1 effects on the inflammatory 
profile.
SIRT-1 controls the acetylation of transcriptional regu-
lators involved in adipogenesis and fatty acid oxidation 
[31]. The anti-adipogenic effects of resveratrol have been 
demonstrated in preclinical models, while controversial 
results were found in humans [12, 13]. We found a signifi-
cant reduction in body fat percentage in individuals with 
higher SIRT-1 expression. However, this effect was lost 
when placebo patients were excluded. These results suggest 
Fig. 1  SIRT-1, H3K56ac, and 
p53ac protein expression in 
PBMCs recovered from T2DM 
patients submitted to resveratrol 
supplementation or placebo. 
a Cell extracts from T2DM 
patients’ PBMCs (subject 
1–6) submitted to placebo 
were analyzed for SIRT-1, 
H3K56ac, and p53ac content 
at baseline (t0) and at the trial 
end (6 m). Protein levels were 
normalized to beta actin, H3 
and p53 content, respectively. 
The values reported represent 
the relative amount (ra) of 
protein expression obtained by 
densitometric analysis. b Cell 
extracts from T2DM patients’ 
PBMCs (subject 7–12) submit-
ted to resveratrol 40 mg/day 
supplementation (Resv40) were 
lysed and analyzed for SIRT-1, 
H3K56ac, and p53ac content at 
baseline (t0) and at the trial end 
(6 m). Protein levels were nor-
malized to beta actin, H3 and 
p53 content, respectively. The 
values reported represent the 
relative amount (ra) of protein 
expression obtained by densito-
metric analysis. c Cell extracts 
from T2DM patients’ PBMCs 
(subject 13–18) submitted to 
resveratrol 500 mg/day sup-
plementation (Resv500) were 
lysed and analyzed for SIRT-1, 
H3K56ac, and p53ac content 
at baseline (t0) and at the trial 
end (6 m). Protein levels were 
normalized to beta actin, H3, 
and p53 content, respectively. 
The values reported represent 
the relative amount (ra) of 
protein expression obtained by 
densitometric analysis
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that SIRT-1 plays a role as an anti-adipogenic factor, while 
suggesting that different epigenetic mechanisms may be 
involved in SIRT-1-mediated anti-adipogenic effects.
SIRT-1 has also been shown to regulate glucose and lipid 
metabolism and therefore reduce cardiovascular risk factors 
[30, 31]. We failed to find any association between SIRT-1 
expression and metabolic variables. Highest SIRT-1 tertile 
patients showed increased HbA1c values at baseline and, a 
worse, though not significantly different metabolic profile 
overall. Compensatory SIRT-1 activation might be hypoth-
esized; otherwise, it may be considered a casual finding.
Clinical implications
Although the physio-pathological mechanisms impli-
cated are quite complex and multiple confounders may 
have biased our results, we herein provide evidence that 
boosting SIRT-1 expression translates into a significant 
reduction in H3K56ac, an epigenetic marker of oxida-
tive stress-mediated damage, and into improvements in 
antioxidant activity. Understanding SIRT-1’s role in the 
in vivo regulation of human metabolism and health still 
remains a challenging question and is worthy of further 
ad hoc clinical trials. Generally, advances in therapy have 
Fig. 2  Relative amount of SIRT-1, H3K56ac, and p53ac protein 
expression in PBMCs recovered from T2DM patients submitted to 
resveratrol supplementation or placebo. a The value reported repre-
sents the relative amount of protein expression obtained by densito-
metric analysis of cell extract analyzed in Fig. 1a. Cell extract from 
T2DM patient’ PBMCs (subject 1–6) submitted to placebo was lysed 
and analyzed for SIRT-1, H3K56ac, and p53ac content at baseline 
(t0) and at trial end (6  m). Protein levels were normalized to beta 
actin, H3, and p53 content, respectively. b The value reported rep-
resents the relative amount of protein expression obtained by den-
sitometric analysis of cell extract analyzed in Fig.  1b. Cell extract 
from T2DM patient’ PBMCs (subject 7–12) submitted to resveratrol 
40  mg/day supplementation (Resv40) was lysed and analyzed for 
SIRT-1, H3K56ac, and p53ac content at baseline (t0) and at trial end 
(6 m). Protein levels were normalized to beta actin, H3, and p53 con-
tent, respectively. c The value reported represents the relative amount 
of protein expression obtained by densitometric analysis of cell 
extract analyzed in Fig. 1c. Cell extract from T2DM patient’ PBMCs 
(subject 13–18) submitted to resveratrol 500 mg/day supplementation 
(Resv500) was lysed and analyzed for SIRT-1, H3K56ac, and p53ac 
content at baseline (t0) and at trial end (6 m). Protein levels were nor-
malized to beta actin, H3, and p53 content, respectively
Table 4  Multiple logistic 
regression model. Associations 
between the highest tertile 
of delta SIRT-1 value and 
median value of delta H3K56ac 
(upper), median value of TAS 
(middle), and delta percentage 
body fat (lower) in all arms 
of the trial (left) or including 
only individuals submitted to 
resveratrol supplementation 
(right)
All arms Resveratrol arms
OR 95% CI P OR 95% CI P
Delta H3K56ac 0.66 0.44–0.99 0.04 0.67 0.43–1.04 0.07
Age 1.05 0.99–1.10 0.10 1.02 0.96–1.08 0.58
Male gender 1.84 0.76–4.47 0.17 1.27 0.49–3.31 0.62
Treatment with resveratrol 3.58 1.29–9.90 0.01 –
Delta TAS 1.01 1.00–1.02 0.04 1.01 0.99–1.02 0.05
Age 1.04 0.99–1.10 0.11 1.02 0.96–1.08 0.50
Male gender 2.02 0.83–4.95 0.12 1.43 0.54–3.79 0.47
Treatment with resveratrol 3.09 1.16–8.22 0.02 –
Delta percent body fat 0.75 0.58–0.96 0.02 0.81 0.63–1.05 0.11
Age 1.05 0.98–1.11 0.14 1.02 0.95–1.08 0.75
Male gender 2.37 0.94–5.96 0.07 1.58 0.59–4.21 0.35
Treatment with resveratrol 3.65 1.36–9.81 0.01 –
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led to a significant decline in diabetes-associated com-
plications; however, cardiovascular risk is still a relevant 
clinical problem. Recently, attention has been devoted 
to defining a diabetes epigenetic signature which would 
allow advance in developing new therapeutic options. The 
results of the present study suggest that histone deacety-
lase-based therapy could remove one epigenetic tag and 
change the ROS balance in diabetic patients. Thus, future 
efforts should be made to clearly assess and correlate the 
efficacy of epigenetic targeting approaches to the clinical 
outcomes in T2DM patients.
Limitations
Study power was originally calculated to detect an effect size 
of 0.5 on CRP value [17]. The sample size may have there-
fore been too small to find differences in subgroups. This 
was probably the case in analyses performed after excluding 
Placebo arm patients.
We did not measure plasmatic concentrations of resvera-
trol or its metabolites, meaning that actual substance expo-
sure cannot be determined. Patient compliance could, how-
ever, be considered adequate, on the basis of phone calls, 
capsule counts and the consistent proportional increment in 
TAS levels with increasing resveratrol doses. The strengths 
of the present study were the large number of metabolic 
variables analyzed and the centralized, blindly analyzed, 
measurements.
Conclusion
These data suggest that SIRT-1-mediated changes in the 
epigenome and in the antioxidant response might impact on 
diabetes-associated risk factors.
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